A few commenters expressed that ASCs generally do not have the infrastructure nor the resources to meet the requirements of those measures, such as social workers on staff or knowledge of resources in a patient's own community as many patients travel for ASC care
During the application period, the peptide stimulates gene expression related to collagen production, elastin synthesis, and growth factor secretion, creating a regenerative environment within hair follicles
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
Synergistic Integration Together, these three peptides address the complete regeneration cascade: initial response and inflammation control (BPC-157), cellular migration and reorganization (TB-500), and extracellular matrix synthesis and maturation (GHK-Cu)
The Wald test was used to derive P values and log 2 (fold change)
This Guidance has helped many of our members to have their injections reinstated
